Protalix BioTherapeutics (PLX) Competitors $2.31 -0.02 (-0.86%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$2.32 +0.00 (+0.22%) As of 03/3/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PLX vs. BCAX, SANA, RLAY, TYRA, DNTH, ABUS, VALN, GHRS, PHAR, and LENZShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Bicara Therapeutics (BCAX), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), Dianthus Therapeutics (DNTH), Arbutus Biopharma (ABUS), Valneva (VALN), GH Research (GHRS), Pharming Group (PHAR), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Bicara Therapeutics Sana Biotechnology Relay Therapeutics Tyra Biosciences Dianthus Therapeutics Arbutus Biopharma Valneva GH Research Pharming Group LENZ Therapeutics Protalix BioTherapeutics (NYSE:PLX) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment. Does the MarketBeat Community prefer PLX or BCAX? Bicara Therapeutics received 1 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Bicara Therapeutics an outperform vote while only 76.92% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes1076.92% Underperform Votes323.08% Bicara TherapeuticsOutperform Votes11100.00% Underperform VotesNo Votes Does the media refer more to PLX or BCAX? In the previous week, Bicara Therapeutics had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Bicara Therapeutics and 1 mentions for Protalix BioTherapeutics. Bicara Therapeutics' average media sentiment score of 1.00 beat Protalix BioTherapeutics' score of 0.50 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, PLX or BCAX? Protalix BioTherapeutics has higher revenue and earnings than Bicara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$45.67M3.72$8.31M-$0.13-17.77Bicara TherapeuticsN/AN/AN/AN/AN/A Do analysts recommend PLX or BCAX? Protalix BioTherapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 549.35%. Bicara Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 224.41%. Given Protalix BioTherapeutics' higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is PLX or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Bicara Therapeutics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Bicara Therapeutics N/A N/A N/A Do institutionals & insiders hold more shares of PLX or BCAX? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.3% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryBicara Therapeutics beats Protalix BioTherapeutics on 10 of the 14 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$170.10M$3.08B$5.81B$19.94BDividend YieldN/A1.51%4.75%3.90%P/E Ratio-17.7728.6624.9534.16Price / Sales3.72403.87375.5530.29Price / Cash17.80168.6838.0517.60Price / Book4.913.487.334.70Net Income$8.31M-$71.55M$3.18B$1.02B7 Day Performance-2.94%-5.00%-2.87%-2.20%1 Month Performance-8.33%-10.68%-6.77%-3.99%1 Year Performance47.13%-22.37%12.32%8.16% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.4372 of 5 stars$2.31-0.9%$15.00+549.4%+42.6%$170.10M$45.67M-17.77200High Trading VolumeBCAXBicara TherapeuticsN/A$12.62-3.0%$41.20+226.6%N/A$687.27MN/A0.0032SANASana Biotechnology2.8991 of 5 stars$2.95-2.2%$14.25+383.9%-78.4%$659.76MN/A-2.11380Upcoming EarningsRLAYRelay Therapeutics3.1358 of 5 stars$3.92-0.1%$20.50+423.6%-68.3%$655.29M$25.55M-1.50330Earnings ReportTYRATyra Biosciences1.7752 of 5 stars$12.92-1.9%$30.50+136.2%-43.8%$653.50MN/A-8.0220Short Interest ↑DNTHDianthus Therapeutics1.845 of 5 stars$21.70-8.3%$46.83+115.8%-23.8%$651.28M$5.37M-8.8080ABUSArbutus Biopharma2.1698 of 5 stars$3.38-1.3%$5.50+63.0%+22.6%$639.54M$6.74M-7.8590News CoverageVALNValneva2.857 of 5 stars$7.90+6.1%$17.00+115.3%-3.5%$639.11M$165.52M-60.50700GHRSGH Research2.0226 of 5 stars$12.08-3.4%$30.25+150.4%+8.4%$629.56MN/A-15.3210Earnings ReportShort Interest ↑PHARPharming Group2.679 of 5 stars$9.17+3.5%$27.00+194.4%-20.7%$623.84M$245.32M-35.27280Short Interest ↓Positive NewsGap UpLENZLENZ Therapeutics2.1498 of 5 stars$22.65-3.6%$35.40+56.3%N/A$622.74MN/A0.00110News Coverage Related Companies and Tools Related Companies Bicara Therapeutics Alternatives Sana Biotechnology Alternatives Relay Therapeutics Alternatives Tyra Biosciences Alternatives Dianthus Therapeutics Alternatives Arbutus Biopharma Alternatives Valneva Alternatives GH Research Alternatives Pharming Group Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PLX) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
